The study will enroll approximately 40 participants. The study is composed of 2 parts. Part 1 (single-rising dose [SRD], alternating panel design) and Part 2 (multiple-rising dose [MRD], sequential panel design). Part 1 consists of 2 cohorts, participants will be randomly assigned to one of the two treatment sequences of 4 and 3 periods in cohorts 1 and 2 respectively: